SynthesisChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Global burden of moyamoya syndrome in pediatric sickle cell disease and implications for the neurosurgical workforce: a systematic review.
Synthesis in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aims of the study were twofold: 1) quantify the global burden of pSCD|MMS, and 2) estimate the number of children who warrant specialist evaluation for possible surgical revascularization.
methodsA systematic review was conducted following PRISMA guidelines. Clinical data extracted included number of patients with pSCD, pSCD-MMS, and those who underwent surgical revascularization. Using weighted proportions and 2021 Institute for Health Metrics and Evaluation (IHME) global estimates for pSCD, for each WHO region we estimated the burden of pSCD|MMS, and the volume of pSCD|MMS patients who underwent surgical revascularization.
resultsOf the 6,845 studies identified, 14 were included. Nine (64%) studies were from AMR, 2 (14%) studies from EMR, 1 study (7%) from EUR, 1 study (7%) from AFR, and 1 (7%) multicenter study from AMR and EUR. Of the 2045 pSCD patients between the ages of 1-21 years identified, 1.5% were diagnosed with pSCD|MMS. Of 279 pSCD|MMS patients, 49.8% underwent surgical revascularization. The projected number of pSCD|MMS cases worldwide was 36,587, equating to 18,219 potentially benefiting from surgical revascularization. Across WHO regions, the African region harbors the largest number of projected pSCD|MMS cases (32,189) including 16,030 candidates for surgical consideration. Projections should be interpreted cautiously given the limited number and geographic distribution of the available studies.
conclusionThe vast majority of pSCD and pSCD|MMS burden resides in Africa, wherein SCD-related infrastructure is often limited. Sufficient capacity building for diagnostic accuracy and screening coupled with maximal medical therapy for pSCD, and robust neurosurgical infrastructure is required to improve longitudinal SCD care, mitigate neurologic complications and enhance functional outcomes. Derived from a limited body of published literature, these estimates should be considered exploratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.